Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis.

Emery P, Vlahos B, Szczypa P, Thakur M, Jones HE, Woolcott J, Santos Estrella PV, Rolland C, Gibofsky A, Citera G, Sockalingam S, Marshall L.

J Rheumatol. 2020 Apr;47(4):493-501. doi: 10.3899/jrheum.181398. Epub 2019 Jun 1.

PMID:
31154413
2.

A better look at rheumatoid arthritis: Using imaging to improve patient outcomes.

Gibofsky A, Thiele R.

Semin Arthritis Rheum. 2019 Feb;48(4):763. doi: 10.1016/j.semarthrit.2018.12.004. Epub 2018 Dec 21. No abstract available.

PMID:
30655092
3.

Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys.

Gibofsky A, Galloway J, Kekow J, Zerbini C, de la Vega M, Lee G, Lee EY, Codreanu C, Koehn C, Steinberg K, Bananis E, de Leon DP, Maniccia A, Dikranian A; RA NarRAtive global advisory panel.

Health Qual Life Outcomes. 2018 Nov 9;16(1):211. doi: 10.1186/s12955-018-1035-3.

4.

Short-term costs associated with non-medical switching in autoimmune conditions.

Gibofsky A, Skup M, Yang M, Mittal M, Macaulay D, Ganguli A.

Clin Exp Rheumatol. 2019 Jan-Feb;37(1):97-105. Epub 2018 Jun 25.

PMID:
29998841
5.

Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.

Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD.

Clin Rheumatol. 2018 Sep;37(9):2331-2340. doi: 10.1007/s10067-018-4113-3. Epub 2018 Apr 25.

PMID:
29696436
6.

Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors.

Gibofsky A, Skup M, Mittal M, Johnson SJ, Davis M, Chao J, Rubin DT.

Curr Med Res Opin. 2017 Nov;33(11):1945-1953. doi: 10.1080/03007995.2017.1375903. Epub 2017 Sep 21.

PMID:
28870101
7.

Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review.

Lau CS, Gibofsky A, Damjanov N, Lula S, Marshall L, Jones H, Emery P.

Rheumatol Int. 2017 Nov;37(11):1789-1798. doi: 10.1007/s00296-017-3780-8. Epub 2017 Aug 29. Review.

8.

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

Yazici Y, McAlindon TE, Fleischmann R, Gibofsky A, Lane NE, Kivitz AJ, Skrepnik N, Armas E, Swearingen CJ, DiFrancesco A, Tambiah JRS, Hood J, Hochberg MC.

Osteoarthritis Cartilage. 2017 Oct;25(10):1598-1606. doi: 10.1016/j.joca.2017.07.006. Epub 2017 Jul 13.

9.

Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis.

Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6.

10.

Sex differences in gout characteristics: tailoring care for women and men.

Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD.

BMC Musculoskelet Disord. 2017 Mar 14;18(1):108. doi: 10.1186/s12891-017-1465-9.

11.

Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial.

Strand V, Bergman M, Singh JA, Gibofsky A, Kivitz A, Young C.

Clin Rheumatol. 2017 Jun;36(6):1357-1367. doi: 10.1007/s10067-017-3569-x. Epub 2017 Feb 13.

PMID:
28194525
12.

Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study.

Altman R, Hochberg M, Gibofsky A, Jaros M, Young C.

Curr Med Res Opin. 2015 Dec;31(12):2331-43. doi: 10.1185/03007995.2015.1112772.

PMID:
26503347
13.

Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.

Alten R, Holt R, Grahn A, Rice P, Kent J, Buttgereit F, Gibofsky A.

Scand J Rheumatol. 2015;44(5):354-8. doi: 10.3109/03009742.2015.1038582. Epub 2015 Jun 26.

14.

Low-dose SoluMatrix diclofenac : a review of safety across two Phase III studies in patients with acute and osteoarthritis pain.

Gibofsky A, Altman R, Daniels S, Imasogie O, Young C.

Expert Opin Drug Saf. 2015 Aug;14(8):1327-39. doi: 10.1517/14740338.2015.1047760. Epub 2015 May 25. Review.

PMID:
26004029
15.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12. Review.

16.

Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety study.

Altman RD, Strand V, Hochberg MC, Gibofsky A, Markenson JA, Hopkins WE, Cryer B, Kivitz A, Nezzer J, Imasogie O, Young CL.

Postgrad Med. 2015 Jun;127(5):517-28. doi: 10.1080/00325481.2015.1040716. Epub 2015 Apr 27.

PMID:
25913498
17.

Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).

Gibofsky A, Cannon GW, Harrison DJ, Joseph GJ, Bitman B, Chaudhari S, Collier DH.

Clin Exp Rheumatol. 2015 May-Jun;33(3):297-301. Epub 2015 Feb 18.

PMID:
25738333
18.

The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network.

Harrold LR, Reed GW, Harrington JT, Barr CJ, Saunders KC, Gibofsky A, Greenberg JD, John A, Devenport J, Kremer JM.

BMC Musculoskelet Disord. 2014 Nov 21;15:389. doi: 10.1186/1471-2474-15-389.

19.
20.

Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A Synopsis.

Gibofsky A.

Am J Manag Care. 2014 May;20(7 Suppl):S128-35.

PMID:
25180621
21.

Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study.

Gibofsky A, Hochberg MC, Jaros MJ, Young CL.

Curr Med Res Opin. 2014 Sep;30(9):1883-93. doi: 10.1185/03007995.2014.946123. Epub 2014 Aug 6.

PMID:
25050589
22.

Acute rheumatic fever and streptococci: the quintessential pathogenic trigger of autoimmunity.

Chakravarty SD, Zabriskie JB, Gibofsky A.

Clin Rheumatol. 2014 Jul;33(7):893-901. doi: 10.1007/s10067-014-2698-8. Epub 2014 Jun 4. Review.

PMID:
24894108
23.

Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study.

Gibofsky A, Silberstein S, Argoff C, Daniels S, Jensen S, Young CL.

Postgrad Med. 2013 Sep;125(5):130-8. doi: 10.3810/pgm.2013.09.2693.

PMID:
24113671
24.

Proceedings of the 2013 Rheumatology Winter Clinical Symposia.

Kavanaugh A, Fleischmann R, Bergman MJ, Ruderman E, Troum O, Wells AF, Martin G, Calabrese LH, Gibofsky A, Strand V, Cush JJ.

Semin Arthritis Rheum. 2013 Jun;42(6):667-73. doi: 10.1016/j.semarthrit.2013.04.001. Review.

PMID:
23731828
25.

Delayed-release prednisone - a new approach to an old therapy.

Buttgereit F, Gibofsky A.

Expert Opin Pharmacother. 2013 Jun;14(8):1097-106. doi: 10.1517/14656566.2013.782001. Epub 2013 Apr 18. Review.

PMID:
23594208
26.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34. doi: 10.1136/annrheumdis-2013-203348. No abstract available.

PMID:
23532441
27.

Comparative effectiveness of current treatments for rheumatoid arthritis.

Gibofsky A.

Am J Manag Care. 2012 Dec;18(13 Suppl):S303-14.

PMID:
23327518
28.

Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis.

Gibofsky A.

Am J Manag Care. 2012 Dec;18(13 Suppl):S295-302.

PMID:
23327517
29.

The times they are a changin'.

Yazici Y, Gibofsky A.

Rheumatology (Oxford). 2013 Jan;52(1):3-4. doi: 10.1093/rheumatology/kes359. No abstract available.

PMID:
23238978
30.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D.

Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

31.

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.

Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS.

Ann Rheum Dis. 2013 Apr;72(4):583-9. doi: 10.1136/annrheumdis-2012-202470. Epub 2012 Nov 10. Review. Erratum in: Ann Rheum Dis. 2013 Jun;72(6):1110. Murikama, Miho M [corrected to Murakami, Miho].

32.

A phase 2 study evaluating the efficacy and safety of a novel, proprietary, nano-formulated, lower dose oral diclofenac.

Manvelian G, Daniels S, Gibofsky A.

Pain Med. 2012 Nov;13(11):1491-8. doi: 10.1111/j.1526-4637.2012.01479.x. Epub 2012 Oct 8.

PMID:
23043637
33.

Need to develop new nonsteroidal anti-inflammatory drug formulations.

McCarberg B, Gibofsky A.

Clin Ther. 2012 Sep;34(9):1954-63. doi: 10.1016/j.clinthera.2012.08.005. Epub 2012 Aug 30. Review.

PMID:
22939163
34.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036. No abstract available.

PMID:
22460137
35.

The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac.

Manvelian G, Daniels S, Gibofsky A.

Postgrad Med. 2012 Jan;124(1):117-23. doi: 10.3810/pgm.2012.01.2524.

PMID:
22314121
36.

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.

Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM; CORRONA Investigators.

Ann Rheum Dis. 2012 Jul;71(7):1134-42. doi: 10.1136/annrheumdis-2011-150573. Epub 2012 Jan 30.

PMID:
22294625
37.

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.

Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibofsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peña MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Santos Moreno P, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D; Treat to Target Taskforce.

Ann Rheum Dis. 2011 Nov;70(11):1999-2002. doi: 10.1136/ard.2011.154179. Epub 2011 Jul 29.

38.

Erratum to: Treating rheumatoid arthritis to target: an international initiative.

Bernstein EJ, Kay J, Gibofsky A.

Curr Rev Musculoskelet Med. 2011 Sep;4(3):157. doi: 10.1007/s12178-011-9089-4. No abstract available.

39.

Treating rheumatoid arthritis to target: an international initiative.

Bernstein EJ, Kay J, Gibofsky A.

Curr Rev Musculoskelet Med. 2011 Sep;4(3):79-83. doi: 10.1007/s12178-011-9082-y. No abstract available.

40.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
41.

Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database.

Dworkin RH, Peirce-Sandner S, Turk DC, McDermott MP, Gibofsky A, Simon LS, Farrar JT, Katz NP.

Osteoarthritis Cartilage. 2011 May;19(5):483-92. doi: 10.1016/j.joca.2011.02.020. Epub 2011 Mar 23. Review. Erratum in: Osteoarthritis Cartilage. 2011 Jul;19(7):919.

42.

Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?

Singer O, Gibofsky A.

Curr Opin Rheumatol. 2011 May;23(3):288-92. doi: 10.1097/BOR.0b013e328344f2e4. Review.

PMID:
21378570
43.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852. No abstract available.

PMID:
21339216
44.

Musculoskeletal manifestations of thyroid disease.

Anwar S, Gibofsky A.

Rheum Dis Clin North Am. 2010 Nov;36(4):637-46. doi: 10.1016/j.rdc.2010.09.001. Review.

PMID:
21092843
45.

Minimizing cardiovascular complications during the treatment of osteoarthritis.

Whelton A, Gibofsky A.

Am J Ther. 2011 Nov;18(6):466-76. doi: 10.1097/MJT.0b013e3181e1e218. Review.

PMID:
21048434
46.

Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries.

Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, McCroskery P, Baumgartner SW, Markenson JA.

J Rheumatol. 2011 Jan;38(1):21-8. doi: 10.3899/jrheum.100347. Epub 2010 Oct 15.

PMID:
20952478
47.

Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes.

Gibofsky A, Yazici Y.

Ann Rheum Dis. 2010 Jun;69(6):941-2. doi: 10.1136/ard.2010.131730. No abstract available.

PMID:
20498219
48.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D; T2T Expert Committee.

Ann Rheum Dis. 2010 Apr;69(4):631-7. doi: 10.1136/ard.2009.123919. Epub 2010 Mar 9. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519. Ann Rheum Dis. @011 Jul;70(7):1349. van der Heijde, Desirée [corrected to van der Heijde, Désirée].

49.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i2-29. doi: 10.1136/ard.2009.123885. No abstract available. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19995740
50.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH.

Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834. No abstract available. Erratum in: Ann Rheum Dis. 2009 Mar;68(3):452. Kavanaugh, A [added].

PMID:
19022808

Supplemental Content

Loading ...
Support Center